S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
How to Invest in AI's Fast-Growing Market (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
How to Invest in AI's Fast-Growing Market (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
PwC Australia sidelines 9 directors as leak of tax information investigated
The Largest Ever Technology Wave Is Coming! (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
NASDAQ:KMPH

Zevra Therapeutics (KMPH) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$4.48
$6.27
52-Week Range
N/A
Volume
64,100 shs
Average Volume
189,500 shs
Market Capitalization
$200.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25

Zevra Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
∞ Upside
$17.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.31 out of 5 stars

Medical Sector

973rd out of 1,010 stocks

Pharmaceutical Preparations Industry

480th out of 494 stocks


KMPH stock logo

About Zevra Therapeutics (NASDAQ:KMPH) Stock

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

The Largest Ever Technology Wave Is Coming!
This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.
Zevra Therapeutics (NASDAQ:KMPH) Now Covered by StockNews.com
The Largest Ever Technology Wave Is Coming!
This summer, a small tech company will launch a key technology to advance artificial intelligence, or AI, that can think, reason and make decisions like humans. It will change the world, just like electricity did.
Zevra Therapeutics Begins Trading as ZVRA
Breakeven On The Horizon For KemPharm, Inc. (NASDAQ:KMPH)
See More Headlines

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Company Calendar

Last Earnings
3/30/2022
Today
5/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMPH
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.25
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-8,560,000.00
Net Margins
-328.56%
Pretax Margin
-335.26%

Debt

Sales & Book Value

Annual Sales
$10.72 million
Book Value
$3.63 per share

Miscellaneous

Free Float
34,125,000
Market Cap
$200.47 million
Optionable
Optionable
Beta
2.16

Key Executives

  • Richard W. PascoeRichard W. Pascoe
    Chief Executive Officer & Director
  • Travis C. MickleTravis C. Mickle
    President & Director
  • R. LaDuane CliftonR. LaDuane Clifton
    Chief Financial Officer, Secretary & Treasurer
  • Sven Guenther
    Chief Scientific Officer
  • Daniel Gallo
    Senior Vice President-Medical Affairs













KMPH Stock - Frequently Asked Questions

Should I buy or sell Zevra Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zevra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMPH shares.
View KMPH analyst ratings
or view top-rated stocks.

What is Zevra Therapeutics' stock price forecast for 2023?

4 brokers have issued 12-month price targets for Zevra Therapeutics' shares. Their KMPH share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $17.25 in the next twelve months.
View analysts price targets for KMPH
or view top-rated stocks among Wall Street analysts.

How were Zevra Therapeutics' earnings last quarter?

Zevra Therapeutics, Inc. (NASDAQ:KMPH) posted its quarterly earnings data on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

What other stocks do shareholders of Zevra Therapeutics own?
When did Zevra Therapeutics IPO?

(KMPH) raised $60 million in an initial public offering on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is Zevra Therapeutics' stock symbol?

Zevra Therapeutics trades on the NASDAQ under the ticker symbol "KMPH."

Who are Zevra Therapeutics' major shareholders?

Zevra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%), Sabby Management LLC (0.00%), Cutler Group LLC CA (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include David S Tierney, R Laduane Clifton, Richard W Pascoe, Samuel J Braun, Tamara A Seymour and Travis C Mickle.
View institutional ownership trends
.

How much money does Zevra Therapeutics make?

Zevra Therapeutics (NASDAQ:KMPH) has a market capitalization of $0.00 and generates $10.72 million in revenue each year.

How can I contact Zevra Therapeutics?

Zevra Therapeutics' mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The specialty pharmaceutical company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577.

This page (NASDAQ:KMPH) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -